comparemela.com

Latest Breaking News On - Reddys laboratories ltd price - Page 1 : comparemela.com

Dr Reddy s (RDY) Ends Kuwait Study on Avigan for COVID-19

Dr. Reddy s (RDY) Ends Kuwait Study on Avigan for COVID-19 Zacks.com 1/28/2021 Shares of Dr. Reddy’s Laboratories Ltd. RDY fell 4.13% after it announced the termination of the Avigan study conducted in Kuwait, focused on moderate-to-severe COVID patients in a hospital setting. The study is being conducted in partnership with Global Response Aid FZCO (GRA). However, shares of Dr. Reddy’s have soared 48.2% in the past yearcompared with the industry’s growth of 11.9%. © Provided by Zacks.com The data from the Kuwait CVD-04-CD-001 study involving moderate-severe COVID-19 hospitalized patients did not show a statistically significant difference for the primary endpoint (i.e. time to sustained hypoxia resolution) for Aviganversus Placebo. The subgroup analysis of the low-risk study cohort (n=181) showed a 3-day earlier discharge in the Avigan group compared to the placebo group. The subgroup analysis data during the initial interim analysis showed that an antiviral drug

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.